MedTrace Logo

Continuing Treatment With Pegasys and Copegus

NCT00336518 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2006-06-13

No results posted yet for this study

Summary

Primary objective is to measure sustained viral response given to continuation or prolongation of combined Pegasys\&Copegus treatment

Secondary objective is to measure histological response given to continuation or prolongation of combined Pegasys\&Copegus treatment measured by non-invasive methods

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

peginterferon alfa-2a

DRUG

ribavirin

Sponsors & Collaborators

Principal Investigators

  • János Schuller, Dr. · Májbetegekért Alapítvány

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2009-07-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336518 on ClinicalTrials.gov